Prof. Junho Chung's Laboratory
In Memory of Dr. Andrew T. Serafini
Our friend, Dr. Andrew T. Serafini passed away on the 28th February 2024. He has been a close friend and a mentor to all current and former Junholab members and he will be remembered as such.
If you have any materials or memories to be shared with Junholab members or his family, please contact Dr. Jisu Chae (jschaelab@gmail.com).
We develop novel therapeutic antibodies and bio-pharmaceuticals. Anti-hepatocyte growth factor (HGF)-neutralizing antibody (NCT04368507), anti-complement C5 antibody (IM-101, ImmunAbs), anti-FAM19A5 antibody (NCT05143463), anti-CNTN4 antibody (Gena-104, GENOME & Co), and anti-CD19 CAR (chimeric antigen receptor) T cell therapy (NCT053338931) are under clinical development. There are several novel therapeutic agents under preclinical development.
We invent novel platform technologies in the field of bispecific antibodies, antibody drug conjugate (ADC) and chimeric CAR T cell therapy. For example, an anti-cotinine antibody is now used for a new form of switchable CAR T cell therapy and ADC.
We create unique algorithms for deciphering B cell repertoire of human and animals using Machine learning and Next Generation Sequencing (NGS) technology. This research provides us valuable information on the immunity against viral infection, autoimmune disease, neurodegenerative disease and cancer.